ERBB2 and cancer: Similarly, mutations in histone deacetylases were rare, and amplifications, which were more common, occurred more frequently in basal cancers (16.1% versus 8.5% in claudin-low ER-negative/HER2-negative cancers, Fisher’s exact test, p = 0.06, Figure 10).